PainChek (ASX:PCK) said it is compiling additional information collected from its completed clinical study to address questions from the US Food and Drug Administration, and the submission is expected to be the final step in the firm's US De Novo marketing clearance application, according to a Thursday Australian bourse filing.
The firm said the submission is expected to be the final step in the application and will be submitted before the end of June. It added that there is a commitment by the US FDA for a final decision on De Novo regulatory clearance within 75 days after receiving the submission.
It held a final feedback review meeting with the FDA, focused on addressing the regulator's final questions related to the firm's recent US clinical trial results conducted in New York and Iowa.
The firm also recruited a head of business development for the US market and established integration and reseller agreements with PointClickCare and ElderMark.
The firm's shares fell past 25% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。